Peregrine Asset Advisers’s Vanguard Health Care ETF VHT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$324K Buy
1,084
+22
+2% +$6.12K 0.07% 167
2026
Q1
$289K Hold
1,062
0.08% 158
2025
Q4
$306K Hold
1,062
0.09% 135
2025
Q3
$276K Hold
1,062
0.08% 150
2025
Q2
$264K Hold
1,062
0.08% 147
2025
Q1
$281K Hold
1,062
0.11% 133
2024
Q4
$269K Hold
1,062
0.1% 138
2024
Q3
$300K Hold
1,062
0.1% 148
2024
Q2
$282K Hold
1,062
0.11% 134
2024
Q1
$287K Hold
1,062
0.11% 135
2023
Q4
$266K Hold
1,062
0.13% 128
2023
Q3
$250K Buy
+1,062
New +$259K 0.13% 124
2017
Q3
Sell
-64,004
Closed -$9.43M 98
2017
Q2
$9.43M Buy
+64,004
New +$9.05M 6.02% 2
2015
Q3
Sell
-9,450
Closed -$1.32M 105
2015
Q2
$1.32M Hold
9,450
0.99% 23
2015
Q1
$1.28M Buy
+9,450
New +$1.24M 0.84% 34

Other funds holding VHT

Peregrine Asset Advisers's VHT Position: Q2 2026 in Review

Peregrine Asset Advisers increased its Vanguard Health Care ETF (VHT) stake by 2.1% in Q2 2026, buying an estimated $6.12K and bringing the position to 1,084 shares worth $324K. The position accounts for 0.07% of the portfolio, ranked #167.

Peregrine Asset Advisers first reported a position in VHT in Q1 2015 and has held it in 15 quarters since. The position peaked at $9.43M in Q2 2017. 1,112 funds tracked by Wall St. Rank hold VHT as of Q2 2026.

  • Peregrine Asset Advisers held 1,084 shares of Vanguard Health Care ETF worth $324K as of Q2 2026.
  • Peregrine Asset Advisers bought 22 Vanguard Health Care ETF shares in Q2 2026, an estimated $6.12K.
  • Vanguard Health Care ETF made up 0.07% of Peregrine Asset Advisers's portfolio in Q2 2026, its #167 holding.
  • Peregrine Asset Advisers first reported a position in Vanguard Health Care ETF in Q1 2015 and has held it in 15 quarters since.
  • Peregrine Asset Advisers's Vanguard Health Care ETF position peaked at $9.43M in Q2 2017.
  • 1,112 funds tracked by Wall St. Rank held Vanguard Health Care ETF as of Q2 2026.

Based on Peregrine Asset Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.